Mar 8 2010
On January 28, 2010, Chinmax
Medical Systems, Inc., a leading distributor of clinical diagnostics in China,
filed a civil complaint in the People's Court of Yangpu District, Shanghai
against Inverness Medical Beijing Co. Ltd., a subsidiary of Inverness Medical
Innovations, Inc. ( IMA).
According to the complaint, Chinmax is the exclusive distributor in China
of diagnostics products manufactured by Biosite Incorporated, a leading
cardiac biomarkers company in San Diego, California, USA. Biosite was acquired
by Inverness Medical Innovations, Inc. (NYSE: IMA) in June 2007. The complaint
accused Inverness Medical Beijing Co. Ltd., along with a second defendant,
Shanghai Tongwei Medical Device Co. Ltd., of infringing Chinmax's exclusive
distribution rights by importing and selling the relevant products in China
without permission. The complaint also accused Inverness Medical Beijing of
infringing Chinmax's proprietary rights to the relevant product registrations
issued by China's State Food and Drug Administration ("SFDA").
Chinmax is seeking from the court a cease and desist order prohibiting the
defendants from importing and selling the relevant products in China. Chinmax
is also asking the court to order Inverness Medical Beijing to return the
relevant product registration documents to Chinmax and stop infringing acts
before China's State Food and Drug Administration ("SFDA").
"We have invested too much in helping Biosite become the market leader in
China to allow the infringement of our rights," said Kevin Yue, President of
Chinmax. "We will vigorously protect our rights, and take necessary actions
against any infringers."
Chinmax has been distributing Biosite products for over 10 years since
1999, and the Biosite Triage products currently have more than 80% of the
heart failure diagnostics market share in China.
Source:
Chinmax Medical Systems, Inc.